Public Employees Retirement System of Ohio acquired a new stake in shares of Puma Biotechnology Inc (NASDAQ:PBYI) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 19,035 shares of the biopharmaceutical company’s stock, valued at approximately $2,279,000. Public Employees Retirement System of Ohio owned about 0.05% of Puma Biotechnology at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Strs Ohio bought a new position in Puma Biotechnology during the 2nd quarter valued at $122,000. Cubist Systematic Strategies LLC bought a new position in Puma Biotechnology during the 2nd quarter valued at $146,000. Sei Investments Co. bought a new position in Puma Biotechnology during the 3rd quarter valued at $256,000. Kazazian Asset Management LLC bought a new position in Puma Biotechnology during the 2nd quarter valued at $209,000. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Puma Biotechnology by 5.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 140 shares during the period. Hedge funds and other institutional investors own 96.00% of the company’s stock.
Shares of Puma Biotechnology Inc (PBYI) opened at $98.85 on Tuesday. The firm has a market cap of $3,750.00, a price-to-earnings ratio of -12.07 and a beta of 0.73. Puma Biotechnology Inc has a twelve month low of $28.35 and a twelve month high of $136.90.
In related news, insider Charles R. Eyler sold 1,322 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 21.10% of the stock is owned by company insiders.
A number of analysts have weighed in on PBYI shares. Stifel Nicolaus increased their target price on shares of Puma Biotechnology from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, October 2nd. Credit Suisse Group reissued an “outperform” rating and set a $136.00 target price on shares of Puma Biotechnology in a report on Wednesday, September 27th. BidaskClub raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 3rd. Leerink Swann increased their target price on shares of Puma Biotechnology to $140.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Finally, Citigroup reissued a “buy” rating and set a $156.00 target price (up from $114.00) on shares of Puma Biotechnology in a report on Thursday, October 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $130.67.
COPYRIGHT VIOLATION WARNING: “Public Employees Retirement System of Ohio Acquires New Position in Puma Biotechnology Inc (PBYI)” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.com-unik.info/2018/01/02/public-employees-retirement-system-of-ohio-acquires-new-position-in-puma-biotechnology-inc-pbyi.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).
What are top analysts saying about Puma Biotechnology? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Puma Biotechnology and related companies.